Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mutant p53 refers to tumor protein p53 with mutations, most commonly missense mutations in the DNA-binding domain. These mutations lead to loss of normal tumor suppressor functions, such as cell cycle arrest and apoptosis, and often confer new oncogenic gain-of-function properties, including promoting tumor progression, metastasis, angiogenesis, and metabolic reprogramming. Mutant p53 is a major therapeutic target in cancer.
Varies depending on the specific mutant p53 and therapeutic approach; strategies include restoring wild-type p53 function, inhibiting mutant p53 gain-of-function activities, or targeting downstream pathways affected by mutant p53.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Protein p53 (Mutant) (mutant p53).